Syntara Limited to Host Investor Webinar on Drug Development Progress

Pharmaxis Ltd (AU:SNT) has released an update.

Syntara Limited, a clinical stage drug development company listed on the ASX, is set to update investors in an upcoming webinar, highlighting its promising pipeline including the lead candidate SNT-5505 for myelofibrosis. The company is advancing several phase 2 studies in high unmet need areas, while also collaborating on treatments for neurodegenerative diseases and fibrosis. With a strong focus on innovation, Syntara aims to make significant strides in treating complex conditions.

For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.